× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • OnabotulinumtoxinA and CGRP mAbs are widely used treatments for chronic migraine.1
  • There is limited data on the efficacy and safety of onabotulinumtoxinA in combination with CGRP mAb treatment in patients partially responsive to onabotulinumtoxinA.1

How was this study conducted?

  • A retrospective chart review of adult patients with chronic migraine (N=153) receiving treatment with onabotulinumtoxinA who were then prescribed additional CGRP mAb medication (fremanezumab, galcanezumab, or erenumab) between May 2018 to May 2019.
  • Patients were excluded if they received any additional therapy during the study period or if their treatment with a CGRP mAb medication was less than 2 months.
  • The primary outcome was the change in number of monthly headache days.